Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. Friboulet L, et al. Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27. Cancer Discov. 2014. PMID: 24675041 Free PMC article.
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L, Sabio J, Poiraudeau L, Annereau M, Menssouri N, Helissey C, Déas O, Aglave M, Ibrahim T, Pobel C, Nobre C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Judde JG, Chauchereau A, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, Massard C, Friboulet L, Fizazi K, Besse B, Scoazec JY, Loriot Y. Bigot L, et al. Among authors: friboulet l. Eur Urol Oncol. 2024 Jun;7(3):527-536. doi: 10.1016/j.euo.2023.10.011. Epub 2023 Oct 27. Eur Urol Oncol. 2024. PMID: 38433714
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.
Menssouri N, Poiraudeau L, Helissey C, Bigot L, Sabio J, Ibrahim T, Pobel C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Chauchereau A, Blanc-Durand F, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, van de Wiel P, den Biezen E, Wesseling-Rozendaal Y, Ponce S, Michiels S, Massard C, Gautheret D, Barlesi F, André F, Besse B, Scoazec JY, Friboulet L, Fizazi K, Loriot Y. Menssouri N, et al. Among authors: friboulet l. Clin Cancer Res. 2023 Nov 1;29(21):4504-4517. doi: 10.1158/1078-0432.CCR-22-3736. Clin Cancer Res. 2023. PMID: 37364000
Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports.
Moog S, Lamartina L, Bani MA, Al Ghuzlan A, Friboulet L, Italiano A, Lacroix L, Postel Vinay S, Tselikas L, Deschamps F, Bonnet B, Pani F, Baudin E, Hadoux J. Moog S, et al. Among authors: friboulet l. Thyroid. 2023 Nov;33(11):1368-1373. doi: 10.1089/thy.2023.0144. Epub 2023 Oct 9. Thyroid. 2023. PMID: 37698883
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P, Mezquita L, Hollebecque A, Lacroix L, Rouleau E, Gazzah A, Bahleda R, Planchard D, Varga A, Baldini C, Postel-Vinay S, Friboulet L, Loriot Y, Verlingue L, Geraud A, Camus MN, Nicotra C, Soria JC, André F, Besse B, Massard C, Italiano A. Martin-Romano P, et al. Among authors: friboulet l. JCO Precis Oncol. 2022 Oct;6:e2100484. doi: 10.1200/PO.21.00484. JCO Precis Oncol. 2022. PMID: 36315916
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.
Vasseur D, Arbab A, Giudici F, Marzac C, Michiels S, Tagliamento M, Bayle A, Smolenschi C, Sakkal M, Aldea M, Sassi H, Dall'Olio FG, Pata-Merci N, Cotteret S, Fiévet A, Auger N, Friboulet L, Facchinetti F, Géraud A, Ponce S, Hollebecque A, Besse B, Micol JB, Italiano A, Lacroix L, Rouleau E. Vasseur D, et al. Among authors: friboulet l. NPJ Precis Oncol. 2024 Feb 26;8(1):51. doi: 10.1038/s41698-024-00544-7. NPJ Precis Oncol. 2024. PMID: 38409229 Free PMC article.
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: friboulet l. Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: friboulet l. Nat Commun. 2024 Oct 4;15(1):8603. doi: 10.1038/s41467-024-52915-0. Nat Commun. 2024. PMID: 39366934 Free PMC article.
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: friboulet l. Nat Commun. 2024 Oct 30;15(1):9370. doi: 10.1038/s41467-024-53775-4. Nat Commun. 2024. PMID: 39478018 Free PMC article. No abstract available.
70 results